Premium
Pharmacokinetics of clindamycin following subcutaneous administration of clindamycin phosphate in the canine
Author(s) -
WEBER D. J.,
BARBIERS A. R.,
LALLINGER A. J.,
NEFF A. W.,
POPE D. G.
Publication year - 1980
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.1980.tb00418.x
Subject(s) - pharmacokinetics , clindamycin , body weight , regimen , chemistry , pharmacology , antibiotics , medicine , biochemistry
Each of two male and two female healthy, non‐fasted mongrel dogs weighing approximately 13.6 kg were given subcutaneous injections of clindamycin‐2‐phosphate sterile solution. The doses were 2.75, 5.51, 11.02 and 21.04 mg clindamycin free base as clindamycin‐2‐phosphate/kg of body weight. Serum samples were assayed for clindamycin bioactivity as a function of time and the pharmacokinetics determined. The elimination curves were biexponential with mean values for α of 0.466 ‐1 and 0.0498 h ‐1 for β. The three lower doses demonstrated linear pharmacokinetics (constant total body clearance) while the highest dose did not. Based on the pharmacokinetics, a dosage regimen of 11.02 mg of clindamycin free base as clindamycin‐2‐phosphate/kg of body weight every 24 h is recommended.